



FOR IMMEDIATE RELEASE:

Contact: Lyndsay Higgins
Cryobanks International
407-834-8333
Fax- 407-834-3533
LHiggins@cryo-intl.com
<http://www.cryo-intl.com>

Cryobanks International, Inc. Licenses Cord Blood Processing System in India

Altamonte Springs, FL December 28, 2005- Cryobanks International, Inc. announced the licensing of its proprietary cord blood processing system to Cryobanks International India Private Limited. The bank is located in New Dehli India. Cryobanks International India Private Limited is scheduled to open in June of 2006 and will become home to one of the largest cord blood processing laboratories in the country. In addition to the New Dehli location, Cryobanks International India Private Limited will open 6 other facilities within the next eighteen months.

India represents one of the largest birth markets in the world with approximately 25 million births each year. "In addition to being one of the most populous countries in the world, India is also rapidly growing, creating significant market opportunities" says Dwight Brunoehler, President and CEO of Cryobanks International, Inc..

Cryobanks International, Inc. began licensing its technology and expertise after the considerable growth of umbilical cord blood banking. The first licensed facility was opened in Athens, Greece in 2005. The company is currently in negotiations to license its proprietary technology to companies in the United Kingdom, Oman, the Emirates and a number of other nations.

About Cryobanks:

Cryobanks International, is a corporation located in Altamonte Springs, FL., which is to be acquired by BioStem, Inc. (OTC: BTEM). The Company is a leader in the collection, processing, and banking of stem cells derived from the umbilical cord immediately after birth. The units of cord blood (CB) are processed and stored by the company for use in unrelated transplants (where the donor is a histocompatible match, but is anonymous and unrelated to the recipient) and for personal storage and use. In recent years, cord blood transplants (CBTs) have become widely recognized as a safe, effective, and in many

ways preferable, alternative to bone marrow transplant (BMT). There is tremendous potential need for CBTs in the United States and worldwide. Cryobanks International is well poised to help meet that need, equipped with an inventory of over 8,500 cord blood units. For more information about Cryobanks International call 1-800-869-8608 or visit the website at www.cryo-intl.com.

Safe Harbor Statement

This press release contains “forward-looking statements” by BioStem, Inc. These statements relate to future events or financial performance and transactions, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements, to be materially different from those contemplated by the forward-looking statements. There can be no assurance that the acquisition described herein will successfully close. We undertake no ongoing obligation, other than that imposed by law, to update these statements. Factors that could affect results, levels of activity, performance or achievements and cause them to materially differ from those contained in the forward-looking statements include the failure to complete the acquisition of Cryobanks, and other factors that can be found in BioStem’s filings with the Securities and Exchange Commission, which can be found at www.sec.gov.

###